Spotlight On... Lobbying dollars pay off with medical device tax suspension; FDA clears OTC hearing test; VHG nabs $13M for respiratory equipment; and more...

Money talks. That's the lesson of the two suspensions of the dreaded 2.3% medical device excise tax. Several prior attempts at ending the tax failed, apparently because Congress couldn't find a "pay-for," but the suspension was passed late last year in a comprehensive deal to avoid another government shutdown that contained several corporate tax cuts and lots of spending. Medtronic spent $10 million on lobbying in 2013 and 2014, while St. Jude Medical chipped in $795,000 toward the effort. AdvaMed was the most vocal critic of the tax, and spent more than $4 million in 2014 and 2015. The money spent lobbying against the tax will generate a handsome return on investment. In 2014, Johnson & Johnson ($JNJ) paid $180 million in device tax payments, Medtronic ($MDT) paid $112 million, Covidien $60 million, Smith & Nephew ($SNN) $25 million and C.R. Bard ($BCR) $3.5 million. More

@FierceMedDev: NIH backs smartphone-based artificial pancreas trials with almost $13M. More | Follow @FierceMedDev

@EmilyWFierce: Pathway Genomics scores $40M in Series E round for genetic test development. Story | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: Scottish researchers develop ingestible 'pill camera' that images non-visible light to detect cancer. More | Follow @VarunSaxena2

> Startup iHear Medical got FDA clearance for the first over-the-counter hearing screener, iHearTest, which is based on World Health Organization (WHO) guidelines on adult hearing loss. More

> Main Street Capital led a $13 million financing for respiratory durable medical equipment company Valley Healthcare Group. More

> Maquet Medical Systems has launched two new intensive care ventilators, one specifically for neonatal use. Both were cleared by the FDA in December. More

Biotech News

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Annapurna adds three new gene therapy programs from Ron Crystal's lab at Weill Cornell. Story | Follow @JohnCFierce

@DamianFierce: I cannot prove that OncoCyte got its name from this generator, but I will take credit anyway. Website | Follow @DamianFierce

> Report: Chinese biopharma Jiangsu Hansoh eyes a $3B IPO. Story

> Gilead lines up for a fast FDA OK with its next-gen hep C combo. More

Pharma News

@FiercePharma: Roche resolves patent war with India's Glenmark over generic Tarceva. More | Follow @FiercePharma

@EricPFierce: 18 months after the #FDA slapped Cadila with a Form 483, it sends a warning letter. News | Follow @EricPFierce

@CarlyHFierce: ICYMI: Shire could nab Baxalta for $32B this week: Bloomberg. Story | Follow @CarlyHFierce

> Teva and Takeda fill in details on new Japan generics JV. More

> Lilly falls short of analyst forecasts with 2016 guidance on the 'weaker end.' Article

Pharma Manufacturing News

> Cadila to buy Zoetis animal drugs and feed plant in India for $29M. Item

> FDA slaps two Cadila facilities with warning letters. More

> Orchid gets favorable report for its formulation facility near Chennai. Story

> Reuters: J&J shopping its Noramco API unit for up to $800M deal. News

> FDA unveils new pharma manufacturing program as part of draft guidance. More

Drug Delivery News

> Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. Story

> Halozyme picks up $150M credit deal on its Roche, Baxalta royalties. More

> Amgen partners with Unilife on wearable injectors, may buy 20% stake in the struggling company. Article

> UCSB team makes toxic transdermal drugs safer with salt formulation. News

> FDA approves nonalcoholic formulation of cancer drug, eliminating risk of intoxication following treatment. More

Pharma Asia News

> Japan's push on innovative drugs gets a budget boost. More

> India's hep C market sets a global pace on cost, access. Report

> Indonesia pharma investment cap eyed as top firms plan new plants. Story

> Sinovac gets China FDA new drug, production nod for HFMD vaccine. Article

> EU and India set Jan. 18 date for talks on GVK drug ban. Item

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.